Cargando…

Successful treatment of necrobiosis lipoidica and associated retinal vasculitis with tumor necrosis factor (TNF)-alpha inhibitor

PURPOSE: To report the clinical and histopathologic features of necrobiosis lipoidica and associated retinal vasculitis and describe successful treatment of both skin and eye manifestations with adalimumab, a tumor necrosis factor (TNF)-alpha inhibitor. OBSERVATIONS: A 35-year-old patient with bipol...

Descripción completa

Detalles Bibliográficos
Autores principales: Panse, Ketaki, Herrera, Manuela, Fung, Maxwell, Brassard, Alain, Moussa, Kareem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407115/
https://www.ncbi.nlm.nih.gov/pubmed/37560554
http://dx.doi.org/10.1016/j.ajoc.2023.101908
_version_ 1785085883436761088
author Panse, Ketaki
Herrera, Manuela
Fung, Maxwell
Brassard, Alain
Moussa, Kareem
author_facet Panse, Ketaki
Herrera, Manuela
Fung, Maxwell
Brassard, Alain
Moussa, Kareem
author_sort Panse, Ketaki
collection PubMed
description PURPOSE: To report the clinical and histopathologic features of necrobiosis lipoidica and associated retinal vasculitis and describe successful treatment of both skin and eye manifestations with adalimumab, a tumor necrosis factor (TNF)-alpha inhibitor. OBSERVATIONS: A 35-year-old patient with bipolar disorder and ocular hypertension was referred for evaluation of bilateral retinal vasculitis. Fluorescein angiography revealed bilateral occlusive retinal vasculitis. Physical exam was notable for multiple annular and round erythematous hyperpigmented and atrophic patches and plaques on both lower extremities. Skin biopsy revealed a diagnosis of necrobiosis lipoidica, a rare granulomatous skin disease. Both the patient's retinal vasculitis and skin patches responded favorably to treatment with adalimumab, a TNF-alpha inhibitor. CONCLUSIONS AND IMPORTANCE: This case highlights the importance of obtaining a complete history and physical exam in patients who present with ocular inflammation, as extraocular manifestations of disease may be present. It also demonstrates the effectiveness of a multidisciplinary approach to evaluation and management of these patients, as both skin and eye involvement were successfully treated with adalimumab, a TNF-alpha inhibitor.
format Online
Article
Text
id pubmed-10407115
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-104071152023-08-09 Successful treatment of necrobiosis lipoidica and associated retinal vasculitis with tumor necrosis factor (TNF)-alpha inhibitor Panse, Ketaki Herrera, Manuela Fung, Maxwell Brassard, Alain Moussa, Kareem Am J Ophthalmol Case Rep Case Report PURPOSE: To report the clinical and histopathologic features of necrobiosis lipoidica and associated retinal vasculitis and describe successful treatment of both skin and eye manifestations with adalimumab, a tumor necrosis factor (TNF)-alpha inhibitor. OBSERVATIONS: A 35-year-old patient with bipolar disorder and ocular hypertension was referred for evaluation of bilateral retinal vasculitis. Fluorescein angiography revealed bilateral occlusive retinal vasculitis. Physical exam was notable for multiple annular and round erythematous hyperpigmented and atrophic patches and plaques on both lower extremities. Skin biopsy revealed a diagnosis of necrobiosis lipoidica, a rare granulomatous skin disease. Both the patient's retinal vasculitis and skin patches responded favorably to treatment with adalimumab, a TNF-alpha inhibitor. CONCLUSIONS AND IMPORTANCE: This case highlights the importance of obtaining a complete history and physical exam in patients who present with ocular inflammation, as extraocular manifestations of disease may be present. It also demonstrates the effectiveness of a multidisciplinary approach to evaluation and management of these patients, as both skin and eye involvement were successfully treated with adalimumab, a TNF-alpha inhibitor. Elsevier 2023-07-26 /pmc/articles/PMC10407115/ /pubmed/37560554 http://dx.doi.org/10.1016/j.ajoc.2023.101908 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Panse, Ketaki
Herrera, Manuela
Fung, Maxwell
Brassard, Alain
Moussa, Kareem
Successful treatment of necrobiosis lipoidica and associated retinal vasculitis with tumor necrosis factor (TNF)-alpha inhibitor
title Successful treatment of necrobiosis lipoidica and associated retinal vasculitis with tumor necrosis factor (TNF)-alpha inhibitor
title_full Successful treatment of necrobiosis lipoidica and associated retinal vasculitis with tumor necrosis factor (TNF)-alpha inhibitor
title_fullStr Successful treatment of necrobiosis lipoidica and associated retinal vasculitis with tumor necrosis factor (TNF)-alpha inhibitor
title_full_unstemmed Successful treatment of necrobiosis lipoidica and associated retinal vasculitis with tumor necrosis factor (TNF)-alpha inhibitor
title_short Successful treatment of necrobiosis lipoidica and associated retinal vasculitis with tumor necrosis factor (TNF)-alpha inhibitor
title_sort successful treatment of necrobiosis lipoidica and associated retinal vasculitis with tumor necrosis factor (tnf)-alpha inhibitor
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407115/
https://www.ncbi.nlm.nih.gov/pubmed/37560554
http://dx.doi.org/10.1016/j.ajoc.2023.101908
work_keys_str_mv AT panseketaki successfultreatmentofnecrobiosislipoidicaandassociatedretinalvasculitiswithtumornecrosisfactortnfalphainhibitor
AT herreramanuela successfultreatmentofnecrobiosislipoidicaandassociatedretinalvasculitiswithtumornecrosisfactortnfalphainhibitor
AT fungmaxwell successfultreatmentofnecrobiosislipoidicaandassociatedretinalvasculitiswithtumornecrosisfactortnfalphainhibitor
AT brassardalain successfultreatmentofnecrobiosislipoidicaandassociatedretinalvasculitiswithtumornecrosisfactortnfalphainhibitor
AT moussakareem successfultreatmentofnecrobiosislipoidicaandassociatedretinalvasculitiswithtumornecrosisfactortnfalphainhibitor